The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway | Zendy

Yi Bao | Zendy; Lei Jiang | Zendy; Haiyan Chen | Zendy; Junjie Zou | Zendy; Zhimin Liu | Zendy; Yongquan Shi | Zendy

Open Access

The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway

Author(s) -

Yi Bao,

Lei Jiang,

Haiyan Chen,

Junjie Zou,

Zhimin Liu,

Yongquan Shi

Publication year - 2015

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000430199

Subject(s) - liraglutide , creb , neuroprotection , adenylyl cyclase , endocrinology , medicine , protein kinase a , pharmacology , sh sy5y , cyclic adenosine monophosphate , advanced glycation end product , glycation , chemistry , receptor , biology , kinase , diabetes mellitus , biochemistry , type 2 diabetes , cell culture , genetics , transcription factor , gene , neuroblastoma

Glucagon-like peptide-1 (GLP-1)-based drugs are being used to achieve better glucose control in patients with type 2 diabetes, and GLP-1 mimetics such as liraglutide have shown therapeutic potential in preventing diabetes-related microvascular and macrovascular complications as well as comorbidities such as neurodegenerative disorders. In the present study, we investigated the effects of liraglutide on primary rat cortical astrocytes treated with advanced glycation end-products (AGEs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research